Avricore's UK Gambit: Financing Fuels Bet on Pharmacy Health Tech

VANCOUVER, British Columbia – June 17, 2026 – For a small-cap innovator on the TSX Venture Exchange, a capital raise is a routine event. But Avricore Health’s recently closed $1.254 million private placement is far more than a simple line item on a balance sheet. It represents a strategic war chest, meticulously assembled to fuel a calculated and potentially transformative expansion into the United Kingdom’s evolving healthcare landscape.

The financing, secured through the issuance of over 25 million units at $0.05 each, provides what CEO Rodger Seccombe described as the “capital strength for its UK expansion.” While the funds are officially earmarked for general working capital, the clear strategic imperative is to execute on a growth plan that increasingly sees the company’s future tied to the UK’s National Health Service (NHS).

This move is not just about crossing the Atlantic; it's about positioning Avricore’s flagship HealthTab™ platform at the epicenter of a global megatrend: the decentralization of healthcare from the hospital to the community pharmacy.

The Strategic Pivot to the UK

Avricore's focus on the UK is a deliberate strategy built on promising early results and favorable regulatory tailwinds. The company is already moving beyond proof-of-concept, with its HealthTab™ system active in NHS pilot programs across North East and North Central London. As of this spring, these programs had already screened over 3,500 patients in local pharmacies.

One particularly telling pilot focused on HbA1c testing for diabetes screening. In just one month, 57 locations completed nearly 2,300 tests. The monthly per-location testing average was a staggering ten times higher than what the company had previously achieved in its established Canadian network, signaling a powerful market pull within the NHS framework.

This momentum is what the new financing is designed to capture. Avricore has publicly stated its goal of having 500 or more active UK locations by mid-2027, with 700 of its partner Abbott’s Afinion™ 2 analyzers already staged in its London office, ready for deployment. The long-term addressable market is vast, encompassing over 10,000 community pharmacies across England’s 42 integrated care boards.

The timing is critical. The NHS Long Term Plan explicitly prioritizes delivering care closer to home, a philosophy that perfectly aligns with HealthTab’s model. More importantly, a seismic shift in the pharmacy profession is set to occur in September 2026, when newly qualified pharmacists in England will graduate as independent prescribers. This change elevates the pharmacist's role from dispenser to clinician, creating an urgent need for the kind of robust, on-site diagnostic infrastructure that Avricore provides.

HealthTab: The Technology Underpinning the Vision

At the core of this expansion is HealthTab™, a platform that is more of a complete ecosystem than a simple testing device. It’s a turnkey solution that integrates best-in-class point-of-care analyzers with a secure, cloud-based software platform. This allows for real-time data capture, quality control monitoring, and seamless integration into the broader digital health infrastructure.

This isn't just about convenience; it's about trust. A key differentiator for Avricore is its commitment to clinical-grade accuracy. Through a partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC’s Cholesterol Reference Method Laboratory Network, HealthTab operates a quality management program that mirrors the rigor of accredited hospital labs. This ensures that results for up to 23 key health biomarkers—from cholesterol to blood sugar—are not just fast, but also reliable and traceable to international standards.

This model has already been validated in Canada, where HealthTab™ is deployed in over 530 pharmacies, including major chains like Rexall. There, it empowers pharmacists to conduct health screenings, offer immediate consultations, and play a more proactive role in managing chronic diseases like diabetes and heart disease. By proving the model at home, Avricore has developed a playbook it now aims to scale in the larger and arguably more structured UK market.

Decoding the Dollars: A Vote of Confidence

From an investment perspective, the $1.254 million financing carries signals that transcend its modest size. The structure, which includes one common share and a half-warrant exercisable at $0.10, is typical for a company at this stage. However, the successful closing in a challenging market for small-cap ventures indicates sustained investor belief in the strategic narrative.

A significant tell is the level of insider participation. Directors and officers contributed $200,000 to the financing, acquiring 4 million units. This act of investing their own capital is a powerful vote of confidence, suggesting that those with the deepest insight into the company’s operations and prospects are bullish on its trajectory. While technically a related-party transaction, it falls within standard securities exemptions and serves as a strong market signal.

This raise is part of a consistent pattern of methodical fundraising to fuel development. With reported revenue of $4.79 million in 2024—a 37% year-over-year increase—the company has demonstrated an ability to generate growth. Now, with a strengthened balance sheet, it can fully commit to what it calls a “transition year” focused on penetrating the NHS.

Riding the Wave of Decentralized Healthcare

Ultimately, Avricore's story is a microcosm of a much larger transformation. The paradigm of healthcare delivery is shifting away from centralized, appointment-based models toward a more distributed and on-demand ecosystem. Community pharmacies, with their unparalleled accessibility—nearly 90% of the population in developed nations lives within a few miles of one—are the natural front lines of this new reality.

The COVID-19 pandemic served as a massive catalyst, accelerating the adoption of pharmacy-based testing and demonstrating the system’s capacity to handle large-scale public health initiatives. Now, the focus is expanding from infectious diseases to the much larger and more persistent challenge of chronic disease management.

By providing the tools for rapid screening, monitoring, and data management, companies like Avricore are enabling pharmacists to practice at the top of their license, alleviating pressure on overburdened primary care physicians and emergency rooms. This shift promises a triple win: greater convenience for patients, reduced costs for the healthcare system, and a more sustainable model for preventative care. With its fresh capital and a clear strategic focus on the receptive UK market, Avricore Health is well-positioned to convert that promise into a tangible business.